Beta%252520blockers

# Beta Blockers ## Overview Beta-adrenergic antagonists competitively block catecholamine binding to beta-receptors. They are classified by receptor selectivity (β1-selective vs. non-selective) and intrinsic sympathomimetic activity (ISA). Some possess ancillary properties like alpha-1 blockade (e.g., carvedilol, labetalol) or vasodilation via nitric oxide (e.g., nebivolol). ## Primary Indications * **Cardiovascular:** Hypertension, atrial fibrillation (rate control), stable heart failure (HFrEF), post-myocardial infarction, angina. * **Other:** Migraine prophylaxis (propranolol), essential tremor, thyrotoxicosis symptoms, performance anxiety, portal hypertension (nadolol/propranolol). ## Adult Dosing * **Metoprolol Succinate (ER):** Start 25–50 mg daily; titrate to max 400 mg/day. * **Carvedilol (IR):** Start 3.125 mg BID; titrate to max 25 mg BID (mild-mod HF) or 50 mg BID (post-MI/high-weight). * **Propranolol (IR):** Hypertension 40 mg BID; start low for other indications (e.g., 10 mg). * **Atenolol:** 25–50 mg once daily; max 100 mg/day (Limited benefit in HFrEF). * **Labetalol:** Hypertension 100 mg BID; max 2400 mg daily. *(Note: Target doses for HFrEF are typically higher than hypertension doses; individual titration required based on hemodynamics.)* ## Pediatric Dosing Dosing is highly indication- and weight-dependent; consult institutional guidelines (e.g., Harriet Lane Handbook). * **Propranolol (Infantile Hemangioma):** 1-3 mg/kg/day divided BID. * **Atenolol (Hypertension):** 0.5–1 mg/kg/day (Max 2 mg/kg/day). * **Metoprolol:** Not commonly used as first-line in pediatrics; 0.5–2 mg/kg/day divided BID. ## Dose Adjustments * **Renal Impairment:** Atenolol and nadolol require significant dose reductions or interval extension in CrCl <30 mL/min. Lipophilic agents (propranolol, carvedilol) generally require no adjustments. * **Hepatic Impairment:** Reduce starting doses for hepatically cleared agents (propranolol, carvedilol). ## Contraindications * Bradycardia (<50–60 bpm depending on clinical status) or second/third-degree AV block without a pacemaker. * Decompensated heart failure. * Cardiogenic shock. * Severe reactive airway disease (asthma/COPD) for non-selective agents. * Severe peripheral vascular disease (relative). ## Adverse Effects * Bradycardia, hypotension, heart block. * Fatigue and exercise intolerance. * Masking of hypoglycemic symptoms (except sweating). * Bronchospasm (non-selective). * Erectile dysfunction. * Raynaud’s phenomenon. ## Key Drug Interactions * **CYP2D6 Inhibitors (e.g., fluoxetine, paroxetine):** Increase levels of metoprolol, carvedilol, and propranolol. * **Non-DHP Calcium Channel Blockers (verapamil, diltiazem):** Excessive additive bradycardia and AV block; combination should be avoided or strictly monitored. * **Insulin/Sulfonylureas:** Beta-blockers may mask tachycardia/tremor associated with hypoglycemia. ## Monitoring * **Heart Rate and Blood Pressure:** Prior to every dose during titration. * **Symptoms:** Monitor for worsening HF (weight gain, dyspnea, edema) and symptoms of hypoglycemia. * **Pulmonary:** Auscultate for wheezing if using non-selective blockers in pts with reactive airway history. ## Clinical Pearls * **Abrupt Withdrawal:** Never stop abruptly; may trigger rebound hypertension, tachycardia, or myocardial ischemia. Taper over 1–2 weeks. * **Selectivity:** "Cardioselective" (β1) medications lose selectivity at higher doses. * **Heart Failure:** Always start "low and go slow" in HFrEF to avoid initial worsening of symptoms. * **Lipophilicity:** Propranolol crosses the blood-brain barrier readily (higher incidence of CNS side effects, i.e., nightmares/depression). *** **Educational Disclaimer:** This information is for educational purposes and does not substitute for professional medical judgment. Always verify current prescribing information, institutional protocols, and patient-specific factors before administration.